Telavancin
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Complicated skin and skin structure infections caused by susceptible Gram-positive bacteria (S. aureus including MRSA, S. pyogenes, other Strep species [S. agalactiae, S. anginosusgroup], or vancomycin sensitive E. faecalis).
- HAP and VAP caused by susceptible isolates of S. aureus.
- It should be reserved for use when alternative agents are not suitable.
NON-FDA APPROVED USES
- S. aureus bacteremia and right-sided endocarditis randomized trial comparing telavancin with standard therapy is under way (NCT02208063)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Complicated skin and skin structure infections caused by susceptible Gram-positive bacteria (S. aureus including MRSA, S. pyogenes, other Strep species [S. agalactiae, S. anginosusgroup], or vancomycin sensitive E. faecalis).
- HAP and VAP caused by susceptible isolates of S. aureus.
- It should be reserved for use when alternative agents are not suitable.
NON-FDA APPROVED USES
- S. aureus bacteremia and right-sided endocarditis randomized trial comparing telavancin with standard therapy is under way (NCT02208063)
There's more to see -- the rest of this topic is available only to subscribers.